Key Highlights

  • Kamada's Dividend has an ex-date of August 27, 2026, payable September 17.
  • The dividend yields approximately 1.97% at current share price levels.
  • Second-quarter 2026 Revenue reached a record $54.9 million, up 23% year over year, with adjusted EBITDA up 29% to $14.1 million.
  • The company maintained $70.1 million in cash and investments even after paying a $14.4 million dividend during the quarter.

Kamada's dividend yields approximately 1.97%, a modest number on the surface, but it's backed by a $14.4 million cash payment the company made without denting its balance sheet. That combination, funding a real distribution while still holding $70 million in reserves, points to genuine cash strength behind a relatively small biopharma name.

Dividend Program and Shareholder Returns

Kamada (NASDAQ:KMDA) paid a Cash Dividend for this payment, with an ex-dividend date of August 27, 2026, payable September 17 to shareholders of record. The dividend yields approximately 1.97% at current market prices. The company's most recent dividend was $0.25 per ordinary share, totaling approximately $14.4 million, a significant Capital return relative to the company's size that was funded while Kamada maintained a strong cash position.

About the Company

Kamada is a biopharmaceutical company focused on specialty plasma-derived therapies, including treatments for alpha-1 antitrypsin deficiency and post-exposure prophylaxis. Products such as KEDRAB, VARIZIG, and HEPAGAM are distributed through healthcare providers and specialty channels, giving the company exposure to both product sales and distribution economics.

Financial Performance Behind the Payout

Kamada reported record second-quarter 2026 revenue of $54.9 million, up 23% year over year. Adjusted EBITDA was $14.1 million, up 29%, producing a 26% margin. First-half revenue reached a record $100.2 million, up 13%, while first-half adjusted EBITDA was $25.7 million, also a 26% margin. Cash, cash equivalents, and short-term investments totaled $70.1 million at June 30, after the company paid its dividend during the quarter.

Growth Led by U.S. Specialty-Plasma Demand

Kamada's growth was led by KEDRAB sales in the United States and stronger Demand for VARIZIG and HEPAGAM, demonstrating strength in its core specialty-plasma portfolio. Management reaffirmed its 2026 full-year guidance, suggesting confidence that growth in commercial products and distribution activities can continue. Investors should monitor product concentration, reimbursement conditions, plasma supply, and the company's ability to translate revenue growth into recurring free cash flow.

Outlook

Kamada's strong cash generation, evidenced by its ability to fund a substantial dividend while maintaining a healthy cash balance, supports confidence in the company's near-term financial position. The durability of this growth depends on sustained demand for specialty immunoglobulin therapies, U.S. market access, and Manufacturing reliability, all of which Warrant continued monitoring.